Product Description
Astodrimer gel is a novel drug which demonstrated favourable outcomes for treatment of patients with bacterial vaginosis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33749959/)
Mechanisms of Action: Bacterial Growth Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Nasal,Vaginal,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Starpharma Pty
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Vaginal Diseases|Vaginosis, Bacterial
Phase 2: Vaginal Diseases|Vaginosis, Bacterial|HIV Infections|Herpes Genitalis
Phase 1: COVID-19|HIV Infections|Acquired Immunodeficiency Syndrome|Herpes Simplex
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12620001371987 | P1 |
Completed |
COVID-19 |
2021-03-08 |
|
| SPL7013-017 | P3 |
Completed |
Vaginosis, Bacterial|Vaginal Diseases |
2016-12-09 |
|
| Harmony | P3 |
Completed |
Vaginosis, Bacterial |
2016-09-09 |
|
| SPL7013-018 | P3 |
Completed |
Vaginal Diseases|Vaginosis, Bacterial |
2016-07-04 |